AR031356A1 - Compuesto lacta mico - Google Patents

Compuesto lacta mico

Info

Publication number
AR031356A1
AR031356A1 ARP010105339A ARP010105339A AR031356A1 AR 031356 A1 AR031356 A1 AR 031356A1 AR P010105339 A ARP010105339 A AR P010105339A AR P010105339 A ARP010105339 A AR P010105339A AR 031356 A1 AR031356 A1 AR 031356A1
Authority
AR
Argentina
Prior art keywords
lacta
mico
compound
procedures
methyl
Prior art date
Application number
ARP010105339A
Other languages
English (en)
Spanish (es)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AR031356A1 publication Critical patent/AR031356A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)
  • Cephalosporin Compounds (AREA)
ARP010105339A 2000-11-17 2001-11-15 Compuesto lacta mico AR031356A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US24965600P 2000-11-17 2000-11-17

Publications (1)

Publication Number Publication Date
AR031356A1 true AR031356A1 (es) 2003-09-17

Family

ID=22944436

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010105339A AR031356A1 (es) 2000-11-17 2001-11-15 Compuesto lacta mico

Country Status (33)

Country Link
US (1) US20040248878A1 (cg-RX-API-DMAC7.html)
EP (1) EP1353910B1 (cg-RX-API-DMAC7.html)
JP (1) JP4116431B2 (cg-RX-API-DMAC7.html)
KR (1) KR20030045194A (cg-RX-API-DMAC7.html)
CN (2) CN101624372A (cg-RX-API-DMAC7.html)
AR (1) AR031356A1 (cg-RX-API-DMAC7.html)
AT (1) ATE362919T1 (cg-RX-API-DMAC7.html)
AU (2) AU2432102A (cg-RX-API-DMAC7.html)
BR (1) BR0115424A (cg-RX-API-DMAC7.html)
CA (1) CA2425497C (cg-RX-API-DMAC7.html)
CY (1) CY1106682T1 (cg-RX-API-DMAC7.html)
CZ (1) CZ20031340A3 (cg-RX-API-DMAC7.html)
DE (1) DE60128587T2 (cg-RX-API-DMAC7.html)
DK (1) DK1353910T3 (cg-RX-API-DMAC7.html)
DZ (1) DZ3454A1 (cg-RX-API-DMAC7.html)
EA (1) EA006919B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP034598A (cg-RX-API-DMAC7.html)
ES (1) ES2286162T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20030385A2 (cg-RX-API-DMAC7.html)
HU (1) HUP0301862A3 (cg-RX-API-DMAC7.html)
IL (1) IL155275A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA03004250A (cg-RX-API-DMAC7.html)
MY (1) MY141607A (cg-RX-API-DMAC7.html)
NO (1) NO325217B1 (cg-RX-API-DMAC7.html)
PE (1) PE20020798A1 (cg-RX-API-DMAC7.html)
PL (1) PL211018B1 (cg-RX-API-DMAC7.html)
PT (1) PT1353910E (cg-RX-API-DMAC7.html)
SK (1) SK287794B6 (cg-RX-API-DMAC7.html)
SV (1) SV2003000741A (cg-RX-API-DMAC7.html)
TW (1) TWI235151B (cg-RX-API-DMAC7.html)
UA (1) UA77165C2 (cg-RX-API-DMAC7.html)
WO (1) WO2002040451A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200303411B (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA74849C2 (en) * 2000-11-17 2006-02-15 Lilly Co Eli Lactam
TWI323256B (en) 2002-12-20 2010-04-11 Glaxo Group Ltd Novel benzazepine derivatives and pharmaceutical compositions comprising said compounds
CN102558155A (zh) 2003-01-14 2012-07-11 阿伦纳药品公司 作为代谢调节剂的芳基和杂芳基衍生物及其所涉及的疾病如糖尿病和高血糖症的预防和治疗
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
RU2404968C2 (ru) 2005-04-08 2010-11-27 Дайити Санкио Компани, Лимитед Пиридилдиметилсульфоновое производное
US8258302B2 (en) 2006-01-31 2012-09-04 Api Corporation Method for producing benzazepinone
TW200920362A (en) 2007-09-11 2009-05-16 Daiichi Sankyo Co Ltd Alkylsulfone derivatives
FR2932800B1 (fr) * 2008-06-20 2015-02-20 Servier Lab Nouveau procede de synthese de la 7,8-dimethoxy-1,3-dihydro- 2h-3-benzazepin-2-one, et application a la synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
BR112013008100A2 (pt) 2010-09-22 2016-08-09 Arena Pharm Inc "moduladores do receptor de gpr19 e o tratamento de distúrbios relacionados a eles."
KR101899014B1 (ko) 2012-01-06 2018-09-17 삼성전자주식회사 비엘디씨 모터의 제어 장치 및 그 방법
CN102690231B (zh) * 2012-04-11 2014-07-09 南京友杰医药科技有限公司 治疗阿尔茨海默病潜在药物司马西特的合成方法
EP2987496B1 (en) 2013-04-19 2018-08-08 National University Corporation Okayama University Treatment agent for cognitive disorders, induced by amyloid -protein, therapeutic agent for alzheimer's disease, and treatment method and pathological analysis method related to these
EP3242666B9 (en) 2015-01-06 2024-12-25 Arena Pharmaceuticals, Inc. Compound for use in treating conditions related to the s1p1 receptor
IL285890B (en) 2015-06-22 2022-07-01 Arena Pharm Inc Slate-free crystal of the arginine salt of (Ar)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-4,3,2,1-tetrahydro-cyclopent[b]indole-3-yl ) acetic acid
MX2019009841A (es) 2017-02-16 2020-01-30 Arena Pharm Inc Compuestos y metodos para el tratamiento de la colangitis biliar primaria.
KR102859841B1 (ko) 2018-06-06 2025-09-12 아레나 파마슈티칼스, 인크. S1p1 수용체와 관련된 병태의 치료 방법
KR20230005163A (ko) 2020-03-26 2023-01-09 씨젠 인크. 다발성 골수종 치료 방법

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL158355A0 (en) * 1996-12-23 2004-05-12 Elan Pharm Inc CYCLOALKYL, LACTAM, LACTONE AND RELATED COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AS beta-AMYLOID PEPTIDE RELEASE INHIBITORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
JP2002518481A (ja) * 1998-06-22 2002-06-25 エラン ファーマシューティカルズ，インコーポレイテッド β−アミロイドペプチドの放出および／またはその合成を阻害するための化合物
CA2390376A1 (en) * 1999-11-09 2001-05-17 William Leonard Scott .beta.-aminoacid compounds useful for inhibiting .beta.-amyloid peptide release and/or its synthesis

Also Published As

Publication number Publication date
DZ3454A1 (fr) 2002-05-23
AU2002224321B2 (en) 2006-10-19
HUP0301862A3 (en) 2007-09-28
CY1106682T1 (el) 2012-05-23
JP4116431B2 (ja) 2008-07-09
IL155275A0 (en) 2003-11-23
NO20032215L (no) 2003-07-16
PL360991A1 (en) 2004-09-20
ZA200303411B (en) 2004-08-02
CA2425497A1 (en) 2002-05-23
NO325217B1 (no) 2008-02-25
MXPA03004250A (es) 2003-09-22
NO20032215D0 (no) 2003-05-15
EP1353910B1 (en) 2007-05-23
JP2004521084A (ja) 2004-07-15
CN1575282A (zh) 2005-02-02
SK5432003A3 (en) 2004-09-08
DK1353910T3 (da) 2007-09-10
PL211018B1 (pl) 2012-03-30
DE60128587T2 (de) 2008-01-31
MY141607A (en) 2010-05-31
HUP0301862A2 (hu) 2003-09-29
PE20020798A1 (es) 2002-09-06
WO2002040451A3 (en) 2003-08-28
AU2432102A (en) 2002-05-27
SV2003000741A (es) 2003-01-13
TWI235151B (en) 2005-07-01
EA200300579A1 (ru) 2003-12-25
WO2002040451A2 (en) 2002-05-23
BR0115424A (pt) 2003-10-21
EP1353910A2 (en) 2003-10-22
CZ20031340A3 (cs) 2004-06-16
HRP20030385A2 (en) 2003-08-31
EA006919B1 (ru) 2006-04-28
PT1353910E (pt) 2007-08-20
CA2425497C (en) 2010-08-17
ATE362919T1 (de) 2007-06-15
US20040248878A1 (en) 2004-12-09
SK287794B6 (sk) 2011-10-04
KR20030045194A (ko) 2003-06-09
DE60128587D1 (de) 2007-07-05
UA77165C2 (en) 2006-11-15
ES2286162T3 (es) 2007-12-01
CN101624372A (zh) 2010-01-13
CN100516047C (zh) 2009-07-22
ECSP034598A (es) 2003-06-25

Similar Documents

Publication Publication Date Title
AR031356A1 (es) Compuesto lacta mico
CY1106366T1 (el) Ενωση λακταμης για την αναστολη της απελευθερωσης ή της συνθεσης βητα-αμυλοειδους πεπτιδιου
SE0101675D0 (sv) Novel composition
ECSP003682A (es) Compuestos para el tratamiento de la isquemia
DE50005437D1 (en) Substituierte thien-3-yl-sulfonylamino(thio)carbonyl-triazolin(thi)one
PL363168A1 (pl) Cyklopentanole, kompozycje zawierające takie związki i sposoby leczenia
EA200300050A1 (ru) Гликопептидфосфонатные производные
SV2004001485A (es) Composicion de ziprasidona y controles sinteticos ref. pc23201
PT1307455E (pt) Inibidores de adesao celular mediada por (alfa)l (beta)2
CY1106132T1 (el) Παραγωγα πιπepιδινης ως αναστολεις καναλιου καλιου
ES2243579T3 (es) Derivados de pirazolopirideno.
MY122829A (en) Linezolid-crystal form ii
NO20043016L (no) 6-aminomorfinan-derivater, fremgangsmate for fremstilling og anvendelse derav
HRP20080057T3 (en) 9,10-alpha,alpha-oh-taxane analogs and methods for production thereof
MXPA03009602A (es) Analogos de nociceptina.
MXPA05008960A (es) Oxazolidinonas de indolona antibacteriales, intermedios para su preparacion y composiciones farmaceuticas que las contienen.
DE60100539D1 (en) Tosylprolin-derivate als thymidylat-synthase inhibitoren
DE69827614D1 (de) Chinoxalindionen
YU26001A (sh) Derivati ureidopiperidina kao selektivni antagonisti ljudskih nk3 receptora
ATE328595T1 (de) Carvedilolpolymorph
ATE364619T1 (de) Tibolonformulierungen
BR0113202A (pt) Compostos de trioxepano
HN2000000089A (es) Polimorfos de un diclohidrato cristalino de azobiciclo (2,2,2) oct - 3 - ilamina y sus composiciones farmaceuticas.
UY27523A1 (es) Tetra-, penta-, hexa-y heptapéptidos con actividad antiangiogénica
DOP2002000329A (es) Composicion solida

Legal Events

Date Code Title Description
FA Abandonment or withdrawal